Biogen Inc. said Friday that it has filed for an offering of 2million shares of common stock. If the offering is completed,Biogen will have 30 million shares outstanding. UnderwritersLehman Brothers, Hambrecht & Quist Inc. and Merrill Lynch andCo. have a 300,000-share overallotment option. Biogen stock(NASDAQ:BGEN) closed down $1.50 at $42.25.

The Cambridge, Mass., company's revenues are generated fromworldwide sales by licensees of five products, including alphainterferon and vaccines and diagnostics for hepatitis. Biogen isdeveloping products to treat cardiovascular disease,inflammatory diseases, AIDS and certain cancers.

(c) 1997 American Health Consultants. All rights reserved.